Brazil Computed Tomography Market Size

Brazil Computed Tomography Market Analysis

The Brazil Computed Tomography Market size is estimated at USD 238.92 million in 2024, and is expected to reach USD 294.19 million by 2029, growing at a CAGR of 4.25% during the forecast period (2024-2029).

The pandemic had an adverse effect on the country. Cancer patients were particularly affected by these activities since the length of time needed for screens, diagnoses, and treatment beginning had a negative impact on outcomes. Additionally, it was stated by the Brazilian National Health Agency (Agência Nacional de Sade - ANS) that non-urgent procedures, examinations, and visits will be postponed in 2020. In Brazil as a whole, screening services are significantly impacted by this. The national government of Brazil responded to COVID-19 by declaring a state of emergency due to the rise in cases, but the lockdown was implemented state-by-state, according to the research report "COVID-19: maintaining essential rehabilitation services across the care continuum" published in BMJ Global Health in May 2020. As a result, healthcare facilities all over Brazil provided inconsistent services. All outpatient facilities and services were shut down entirely in several states.

Numerous research studies have been released to offer light on the pandemic's effects. For instance, computed tomography (CT) was used to assess COVID in the nation, according to a research report published in July 2020 with the title "Computed tomography findings in a Brazilian cohort of 48 patients with pneumonia owing to coronavirus disease." Similar to this, a study with the title "Clinical usefulness of tomographic standards for COVID-19 pneumonia diagnosis: Experience from a Brazilian reference centre" was published in October 2020 at the Universidade Federal do Rio Grande do Sul, Program in Pneumology Sciences, Porto Alegre, RS, Brazil. In the early stages of the Brazilian COVID-19 outbreak, the study assessed the sensitivity, specificity, accuracy, and reproducibility of chest CT standards. A 16-slice CT was used for the chest CT, and patients were placed in the supine position during end-inspiration without receiving any contrast agent. Therefore, these studies would help the market grow. Thus, the market is expected to grow in the future.

Brazilian chronic disease occurrences, particularly those linked to neurological disorders and other chronic diseases, are a major driver of the computed tomography market. The growing research and development activity in the nation also influences its market. Parkinson's disease patients had an average age of 64.51 9.20 years, according to a study titled "Parkinson Anxiety Scale: A Validation Study for the Brazilian Population" published in 2020. This condition clearly illustrates that the rise in the geriatric population will lead to an increase in Parkinson's cases, and as a result, the studied market is anticipated to grow over the forecast period. Additionally, nearly 16% of all radiologists reported that CT imaging was their primary imaging technique, per a study titled "Estimating the productivity of radiologists in Brazil: the search for a benchmark," which was published in April 2020. This suggests that CT-related diagnostic techniques are becoming more prevalent across the nation. Collaboration is another key factor in market growth. In order to assess the safety, tolerability, and effectiveness of intranasal Foralumab in hospitalised patients with severe COVID-19 and pulmonary inflammation, Tiziana Life Sciences plc and FHI Clinical will perform a Phase 2 proof-of-concept trial in Brazil in September 2021. Following 14 days of intranasal delivery, the trial will assess the impact of foralumab on the remission of symptoms by chest computed tomography, inflammatory biomarkers, T-cell subpopulations, safety, and mucosal inflammatory response. Therefore, throughout the projection period, market expansion would be driven by the country's growing use of CT scanners in research and development. Thus, due to abovementioned factors the market is expected to grow in the future.

However, the lack of proper reimbursement and stringent regulatory approval procedures, and the high cost of equipment and CT scan procedures, are expected to hinder the market growth.